Beta Blockers in the Treatment of Periocular Infantile Hemangiomas: A Review

Ann Q Tran, Catherine J Choi, Sara T Wester

Abstract


Infantile hemangiomas (IH) are the most common benign tumor of infancy, and in the periocular region can be associated with permanent visual impairment from amblyopia. Previous treatment options included systemic and local corticosteroids, surgical excision, laser therapy, and in rare cases immunomodulatory therapy, many of which had variable outcomes with undesirable side effect profiles. Since their initial use for IH in 2008, beta blockers have become the mainstay of therapy for periocular IH due to their excellent clinical efficacy and tolerability. While the exact mechanism of action of beta blockers in IH has not been fully elucidated, both oral and topical therapy have demonstrated low rates of adverse events and improved outcomes in the management of periocular IH. This review summarizes the most recent studies on the clinical outcomes, management, and guidelines for the treatment of periocular IH with topical and oral beta blockers.

Keywords


Infantile hemangioma, capillary hemangioma, periocular hemangioma, beta blockers, propranolol, timolol

Full Text:

 Subscribers Only

References


Anderson KR, Schoch JJ, Lohse CM, et al. Increasing incidence of infantile hemangiomas (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weight. J Am Acad Dermatol. 2016;74(1):120-6. doi: 10.1016/j.jaad.2015.08.024.

Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907-13. doi: 10.1111/bjd.12804.

Alniemi ST, Griepentrog GJ, Diehl N, et al. Incidence and clinical characteristics of periocular infantile hemangiomas. Arch Ophthalmol. 2012;130(7):889-93. doi: 10.1001/archophthalmol.2012.213.

Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-7. doi: 10.1542/peds.2007-2767.

Schwartz SR, Blei F, Ceisler E, et al. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. J AAPOS. 2006;10(3):262-8.

Frank RC, Cowan BJ, Harrop AR, et al. Visual development in infants: visual complications of periocular haemangiomas. J Plast Reconstr Aesthet Surg. 2010;63(1):1-8. doi: 10.1016/j.bjps.2008.08.045.

Ni N, Guo S, Langer P. Current concepts in the management of periocular infantile (capillary) hemangioma. Curr Opin Ophthalmol. 2011;22(5):419-25. doi: 10.1097/ICU.0b013e32834994b4.

Friling R, Axer-Siegel R, Ben-Amitai D, et al. Intralesional and sub-Tenon's infusion of corticosteroids for treatment of refractory periorbital and orbital capillary haemangioma. Eye (Lond). 2009;23(6):1302-7. doi: 10.1038/eye.2008.300.

Garzon MC, Lucky AW, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005;52(2):281-6.

Wester ST, Johnson TE. Echographic evidence of regression of a periocular infantile capillary hemangioma treated with systemic propranolol. Ophthalmic Surg Lasers Imaging. 2011; 10;42 Online:e18-21. doi: 10.3928/15428877-20110203-04.

Samimi DB, Alabiad CR, Tse DT. An anatomically based approach to intralesional corticosteroid injection for eyelid capillary hemangiomas. Ophthalmic Surg Lasers Imaging. 2012;43(3):190-5. doi: 10.3928/15428877-20120315-03.

Rappaport B, Mellon RD, Simone A, et al. Defining safe use of anesthesia in children. N Engl J Med. 2011;364(15):1387-90. doi: 10.1056/NEJMp1102155.

Greinwald JH Jr, Burke DK, Bonthius DJ, et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg. 1999;125(1):21-7.

Wilson MW, Hoehn ME, Haik BG, et al. Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology. 2007;114(5):1007-11.

Jiang C, Hu X, Ma G. A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma. Pediatr Dermatol. 2011;28(3):259-66. doi: 10.1111/j.1525-1470.2011.01520.

Léauté-Labrèze C, Dumas de la Roque E, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-51. doi: 10.1056/NEJMc0708819.

Haider KM, Plager DA, Neely DE, et al. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS. 2010;14(3):251-6. doi: 10.1016/j.jaapos.2010.05.002.

Li YC, McCahon E, Rowe NA, et al. Successful treatment of infantile haemangiomas of the orbit with propranolol. Clin Experiment Ophthalmol. 2010;38(6):554-9. doi: 10.1111/j.1442-9071.2010.02327.

Blatt J, Morrell DS, Buck S, et al. β-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr. 2011;50(8):757-63. doi: 10.1177/0009922811405517.

Fabian ID, Ben-Zion I, Samuel C, et al. Reduction in astigmatism using propranolol as first-line therapy for periocular capillary hemangioma. Am J Ophthalmol. 2011;151(1):53-8. doi: 10.1016/j.ajo.2010.07.022.

Missoi TG, Lueder GT, Gilbertson K, et al. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol. 2011;129(7):899-903. doi: 10.1001/archophthalmol.2011.40.

Glasman P, Chandna A, Nayak H, et al. Propranolol and periocular capillary hemangiomas: assessment of refractive effect. J Pediatr Ophthalmol Strabismus. 2014;51(3):165-70. doi: 10.3928/01913913-20140507-03.

Levitt M, Coumou AD, Groeneveld L, et al. Propranolol as first-line treatment in orbital infantile haemangiomas: a case series. Orbit. 2014;33(3):178-83. doi: 10.3109/01676830.2014.884148.

Lynch M, Lenane P, O'Donnell BF. Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients. Clin Exp Dermatol. 2014;39(2):142-5. doi: 10.1111/ced.12210.

Snir M, Reich U, Siegel R, et al. Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol. Eye (Lond). 2011;25(12):1627-34. doi: 10.1038/eye.2011.233.

Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735-46. doi: 10.1056/NEJMoa1404710.

Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. Surv Ophthalmol. 2016;61(1):51-8. doi: 10.1016/j.survophthal.2015.08.006.

Xu DP, Cao RY, Tong S, et al. Topical timolol maleate for superficial infantile hemangiomas: an observational study. J Oral Maxillofac Surg. 2015;73(6):1089-94. doi: 10.1016/j.joms.2014.12.026.

Ciudad Blanco C, Campos Domínguez M, Moreno García B, et al. Episcleral infantile hemangioma successfully treated with topical timolol. Dermatol Ther. 2015;28(1):22-4. doi: 10.1111/dth.12173.

Ge J, Zheng J, Zhang L, et al. Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. Sci Rep. 2016;6:19765. doi: 10.1038/srep19765.

Hu L, Huang HZ, Li X, et al. Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma. Dermatology. 2015;230(2):150-5. doi: 10.1159/000369164.

Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013;131(1):99-108. doi: 10.1542/peds.2012-1128.

Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128-40. doi: 10.1542/peds.2012-1691.

Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855-65. doi: 10.1007/s00431-015-2570-0.

Spence-Shishido AA, Good WV, Baselga E, et al. Hemangiomas and the eye. Clin Dermatol. 2015;33(2):170-82. doi: 10.1016/j.clindermatol.2014.10.009.

Claerhout I, Buijsrogge M, Delbeke P, et al. The use of propranolol in the treatment of periocular infantile hemangiomas: a review. Br J Ophthalmol. 2011;95(9):1199-202. doi: 10.1136/bjo.2010.192245.

Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: What every physician should know. Pediatr Dermatol. 2004;21:1-9.

U. S. Food and Drug Administration. Hemangeol safety and efficacy. 2014; 1-18; Reference ID: 3471590. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf

Siegel DH, Tefft KA, Kelly T, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke. 2012;43(6):1672-4. doi: 10.1161/STROKEAHA.112.650952.

Cushing SL, Boucek RJ, Manning SC, SidburyR, Perkins JA. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head NeckSurg. 2011;144(1):78–84. doi: 10.1177/0194599810390445.

Jacks SK, Kertesz NJ, Witman PM, et al. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas. J Am Acad Dermatol. 2015;73(2):255-7. doi: 10.1016/j.jaad.2015.05.015.

Kumar MG, Coughlin C, Bayliss SJ. Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines. Pediatr Dermatol. 2015;32(2):171-9. doi: 10.1111/pde.12435.

Shah SD, Baselga E, McCuaig C, et al. Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. Pediatrics. 2016;137(4). pii: e20151754. doi: 10.1542/peds.2015-1754.

Chinnadurai S, Fonnesbeck C, Snyder KM, et al. Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis. Pediatrics. 2016;137(2):e20153896. doi: 10.1542/peds.2015-3896.

Xu SQ, Jia RB, Zhang W, et al. Beta-blockers versus corticosteroids in the treatment of infantile hemangioma: an evidence-based systematic review. World J Pediatr. 2013;9(3):221-9. doi: 10.1007/s12519-013-0427-z.

Al Dhaybi R, Superstein R, Milet A, et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology. 2011;118(6):1184-8. doi: 10.1016/j.ophtha.2010.10.031.

Burne R, Taylor R; Medscape. Monitoring propranolol treatment in periocular infantile haemangioma. Eye (Lond). 2014;28(11):1281-4. doi: 10.1038/eye.2014.237.

Moehrle M, Leaute-Labreze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol. 2013;30(2):245-9. doi: 10.1111/j.1525-1470.2012.01723.

Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol. 2011;129(3):377-9. doi: 10.1001/archophthalmol.2011.24.

Xue K, Hildebrand GD. Deep periocular infantile capillary hemangiomas responding to topical application of timolol maleate, 0.5%, drops. JAMA Ophthalmol. 2013;131(9):1246-8. doi: 10.1001/jamaophthalmol.2013.4171.

Xue K, Hildebrand GD. Topical timolol maleate 0.5% for infantile capillary haemangioma of the eyelid. Br J Ophthalmol. 2012;96(12):1536-7. doi: 10.1136/bjophthalmol-2012-302396.

Coppens G, Stalmans I, Zeyen T, et al. The safety and efficacy of glaucoma medication in the pediatric population. J Pediatr Ophthalmol Strabismus. 2009;46(1):12-8.




DOI: http://dx.doi.org/10.18103/imr.v2i9.221

Refbacks

  • There are currently no refbacks.
Copyright 2016. All rights reserved.